158 related articles for article (PubMed ID: 35090323)
1. Screening a redox library identifies the anti-tumor drug Hinokitiol for treating intrahepatic cholangiocarcinoma.
Bai P; Ge C; Yang H; Chen H; Wan L; Zhang Y; Zhang B; Zeng Q; Fan Z; Pei X; Yue W; Yan X
Front Biosci (Landmark Ed); 2022 Jan; 27(1):18. PubMed ID: 35090323
[TBL] [Abstract][Full Text] [Related]
2. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
3. Autocrine parathyroid hormone-like hormone promotes intrahepatic cholangiocarcinoma cell proliferation via increased ERK/JNK-ATF2-cyclinD1 signaling.
Tang J; Liao Y; He S; Shi J; Peng L; Xu X; Xie F; Diao N; Huang J; Xie Q; Lin C; Luo X; Liao K; Ma J; Li J; Zhou D; Li Z; Xu J; Zhong C; Wang G; Bai L
J Transl Med; 2017 Nov; 15(1):238. PubMed ID: 29178939
[TBL] [Abstract][Full Text] [Related]
4. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
5. YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation.
Huang CS; Zhu YQ; Xu QC; Chen S; Huang Y; Zhao G; Ni X; Liu B; Zhao W; Yin XY
Clin Transl Med; 2022 Jun; 12(6):e848. PubMed ID: 35696608
[TBL] [Abstract][Full Text] [Related]
6. Brusatol suppresses the growth of intrahepatic cholangiocarcinoma by PI3K/Akt pathway.
Chen Z; He B; Zhao J; Li J; Zhu Y; Li L; Bao W; Zheng J; Yu H; Chen G
Phytomedicine; 2022 Sep; 104():154323. PubMed ID: 35858516
[TBL] [Abstract][Full Text] [Related]
7. High expression of protein tyrosine kinase 7 significantly associates with invasiveness and poor prognosis in intrahepatic cholangiocarcinoma.
Jin J; Ryu HS; Lee KB; Jang JJ
PLoS One; 2014; 9(2):e90247. PubMed ID: 24587299
[TBL] [Abstract][Full Text] [Related]
8. Bufalin targeting CAMKK2 inhibits the occurrence and development of intrahepatic cholangiocarcinoma through Wnt/β-catenin signal pathway.
Zhang H; Dong X; Ding X; Liu G; Yang F; Song Q; Sun H; Chen G; Li S; Li Y; Wang M; Guo T; Zhang Z; Li B; Yang L
J Transl Med; 2023 Dec; 21(1):900. PubMed ID: 38082327
[TBL] [Abstract][Full Text] [Related]
9. The prognostic significance and therapeutic potential of hedgehog signaling in intrahepatic cholangiocellular carcinoma.
Tang L; Tan YX; Jiang BG; Pan YF; Li SX; Yang GZ; Wang M; Wang Q; Zhang J; Zhou WP; Dong LW; Wang HY
Clin Cancer Res; 2013 Apr; 19(8):2014-24. PubMed ID: 23493353
[TBL] [Abstract][Full Text] [Related]
10. SATB1 is a potential therapeutic target in intrahepatic cholangiocarcinoma.
Zhao Z; Ma J; Wu K; Chen L; Yu J; Hu W; Zhang K
Clin Transl Oncol; 2016 Sep; 18(9):878-83. PubMed ID: 26563145
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of 14-3-3ζ expression in intrahepatic cholangiocarcinoma and its clinical implications.
Zhang C; Liu LX; Dong ZR; Shi GM; Cai JB; Zhang PF; Ke AW; Yu JX; Zhou J; Fan J
Tumour Biol; 2015 Mar; 36(3):1781-9. PubMed ID: 25391422
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21.
Chen J; Li Z; Chen J; Du Y; Song W; Xuan Z; Zhao L; Song G; Song P; Zheng S
Clin Transl Oncol; 2020 Mar; 22(3):392-400. PubMed ID: 31264147
[TBL] [Abstract][Full Text] [Related]
13. BET protein inhibition evidently enhances sensitivity to PI3K/mTOR dual inhibition in intrahepatic cholangiocarcinoma.
Miao X; Liu C; Jiang Y; Wang Y; Kong D; Wu Z; Wang X; Tian R; Yu X; Zhu X; Gong W
Cell Death Dis; 2021 Oct; 12(11):1020. PubMed ID: 34716294
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma.
Nishino R; Honda M; Yamashita T; Takatori H; Minato H; Zen Y; Sasaki M; Takamura H; Horimoto K; Ohta T; Nakanuma Y; Kaneko S
J Hepatol; 2008 Aug; 49(2):207-16. PubMed ID: 18490072
[TBL] [Abstract][Full Text] [Related]
15. Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Ling S; Xie H; Yang F; Shan Q; Dai H; Zhuo J; Wei X; Song P; Zhou L; Xu X; Zheng S
J Hematol Oncol; 2017 Feb; 10(1):59. PubMed ID: 28241849
[TBL] [Abstract][Full Text] [Related]
16. The Expression of Yes-Associated Protein (YAP) Maintains Putative Cancer Stemness and Is Associated with Poor Prognosis in Intrahepatic Cholangiocarcinoma.
Sugiura K; Mishima T; Takano S; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takada M; Miyazaki M; Ohtsuka M
Am J Pathol; 2019 Sep; 189(9):1863-1877. PubMed ID: 31220448
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
18. H2A.Z regulates tumorigenesis, metastasis and sensitivity to cisplatin in intrahepatic cholangiocarcinoma.
Yang B; Tong R; Liu H; Wu J; Chen D; Xue Z; Ding C; Zhou L; Xie H; Wu J; Zheng S
Int J Oncol; 2018 Apr; 52(4):1235-1245. PubMed ID: 29532867
[TBL] [Abstract][Full Text] [Related]
19. USP10 promotes intrahepatic cholangiocarcinoma cell survival and stemness via SNAI1 deubiquitination.
Zhu W; Ye B; Yang S; Li Y
J Mol Histol; 2023 Dec; 54(6):703-714. PubMed ID: 37755617
[TBL] [Abstract][Full Text] [Related]
20. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations.
Feng Y; Zhao M; Wang L; Li L; Lei JH; Zhou J; Chen J; Wu Y; Miao K; Deng CX
Cell Death Dis; 2024 Jan; 15(1):34. PubMed ID: 38212325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
